Viking Therapeutics, Inc.
Congressional Trades
No congressional trades in VKTX on record.
Whale Activity
- Increased156
- New74
- Held66
- Decreased119
- Closed63
- No prior filing27
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 9.8M | $321.0M | increased |
| BlackRock, Inc. | 6.2M | $201.0M | decreased |
| STATE STREET CORP | 5.5M | $180.8M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.4M | $175.9M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.7M | $153.8M | increased |
| MORGAN STANLEY | 3.6M | $116.7M | increased |
| TWO SIGMA INVESTMENTS, LP | 2.4M | $78.3M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2M | $71.8M | increased |
| CITADEL ADVISORS LLC | 1.9M | $60.6M | increased |
| AMERICAN CENTURY COMPANIES INC | 1.6M | $53.1M | decreased |
| AQR CAPITAL MANAGEMENT LLC | 1.3M | $41.7M | increased |
| UBS Group AG | 1.1M | $34.8M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Kelly-Gemmell Dorothy ElizabethDirector | Grant / award | +6,333 | $0.00 | $0 | Aug 1, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −148.5K | $33.32 | $4.9M | Jul 29, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −21.2K | $33.47 | $710K | Jul 29, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −18.2K | $33.47 | $610K | Jul 29, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Grant / award | +221.7K | $0.00 | $0 | Jul 28, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Grant / award | +31.7K | $0.00 | $0 | Jul 28, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Grant / award | +31.7K | $0.00 | $0 | Jul 28, 2026 | Form 4 ↗ |
| Aubuchon Neil WilliamChief Commercial Officer | Purchase | +4,475 | $33.50 | $150K | Mar 10, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −1,500 | $32.09 | $48K | Jan 5, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −10.3K | $34.24 | $353K | Jan 5, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −13.9K | $33.38 | $464K | Jan 5, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −32.0K | $32.30 | $1.0M | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −1,600 | $35.07 | $56K | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −10.5K | $34.22 | $359K | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −13.6K | $33.37 | $454K | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −32.0K | $32.29 | $1.0M | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −6,400 | $35.07 | $224K | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −41.3K | $34.22 | $1.4M | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −53.3K | $33.38 | $1.8M | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −132.5K | $32.29 | $4.3M | Jan 5, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 3.6M | $140.0M | 1.30% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.5M | $136.5M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.5M | $98.6M | 0.05% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $56.9M | 0.12% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $52.0M | 0.05% | Jun 30, 2026 |
| Heritage Fund American Century Mutual Funds, Inc. | 1.3M | $42.3M | 0.80% | Jul 31, 2026 |
| Fidelity Advisor Growth Opportunities Fund Fidelity Advisor Series I | 1.1M | $34.8M | 0.10% | Aug 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 569.2K | $18.7M | 0.05% | Aug 31, 2026 |
| iShares Russell Mid-Cap ETF iShares Trust | 467.2K | $18.2M | 0.03% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 553.4K | $18.1M | 0.08% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list VKTX's shares (CUSIP 92686J106), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Corporate Lobbying
No lobbying filings found naming Viking Therapeutics, Inc. as the client.
Government Contracts
No federal contract awards found for Viking Therapeutics, Inc..
U.S. Patents
No USPTO patent applications found for Viking Therapeutics, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M |
| Diluted EPS | -$3.19 | -$1.01 | -$0.91 | -$0.90 | -$0.71 |
| Operating cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M |
| Cash and equivalents | $165.8M | $26.7M | $55.5M | $36.6M | $26.4M |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M |
| Shareholders' equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M |
As Viking Therapeutics, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 11, 2026 ↗
Stock Splits
No stock splits in VKTX's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsOct 28, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 9.01Material agreement · Direct financial obligationSep 28, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 22, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 29, 2026
EDGAR ↗ - 8-K · Items 5.07, 9.01Shareholder voteMay 26, 2026
EDGAR ↗
